Test Available: SARS-CoV-2 (COVID-19) Antibody

Effective May 27, 2020, PathGroup is pleased to announce the availability of a new serologic test for human antibodies to SARS-Cov-2, the viral pathogen associated with COVID-19 (PathGroup Test Code: COVIDAB). On May 3, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Roche Elecsys® SARS-CoV-2 antibody test. The test is for the qualitative detection of total antibodies (including IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection. This test may aid in identification of patients with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection to the SARS-CoV-2 virus.

Click Here to for more information.

Test Update: Ova/Parasite Exam Specimen Requirement Change

Effective June 8, 2020, the following Ova/Parasite tests will change specimen collection containers. For all Ova/Parasite orders placed on or after June 8, Total-Fix collection vials are required for the collection of stool needed for testing. All previous specimen containers will be discontinued. There will be no change in billed CPT codes.

 

Click here for more information.

Test Update: Blood Cultures

Effective March 2, 2020, PathGroup is pleased to announce the implementation of the BD BACTEC system for blood cultures as well as a new test code, CXBLOOD, for blood culture testing.

 

Click here for more information.

Test Update: HLA-B27 Test Code Change

Effective March 16,2020, PathGroup will discontinue HLA-B27 DNA Typing (Test Code: HLABP) and transition to the clinically equivalent HLA-B27 DNA Typing test (Test Code: HB27D).

 

Click here for more information.

ICD Update: Cigna Coverage of Vitamin D Testing

Effective August 19, 2019, Cigna has updated its Vitamin D Testing Medical Coverage Policy (Coverage Policy Number 0526). The updated policy addresses medical necessity and associated ICD-10 codes for serum Vitamin D testing.

 

Click here for more information.